Merck Flexeril Rx-To-OTC Switch To Be Addressed By NDAC
This article was originally published in The Tan Sheet
Executive Summary
The potential Rx-to-OTC switch of Merck's muscle relaxant Flexeril 5 mg (cyclobenzaprine, NDA 21-070) is slated to be discussed at a July 20 joint meeting of FDA's Nonprescription Drugs and Arthritis Advisory Committees. The drug would be indicated for treatment of muscle spasms, dosed three times daily.